title: Ivacaftor, vismodegib, and ingenol mebutate.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.forename: Samuel P
authors.initials: SP
authors.lastname: Eckel
mesh_terms: D000627:Aminophenols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000813:Anilides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004224:Diterpenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy*; D018295:Neoplasms, Basal Cell / Q000188:drug therapy*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: C486592:3-ingenyl angelate; D000627:Aminophenols; D000813:Anilides; D004224:Diterpenes; C538724:HhAntag691; D011725:Pyridines; D015363:Quinolones; C545203:ivacaftor